Pricing Log in Create free account

Longeveron Inc. (LGVN) vs NeuroSense Therapeutics Ltd. (NRSN)

Longeveron Inc. and NeuroSense Therapeutics Ltd. are both Biotechnology companies. Longeveron Inc. and NeuroSense Therapeutics Ltd. are of similar size ($5.1M and $4.6M). NeuroSense Therapeutics Ltd. has the higher net margin (0.00% vs −1,977.6%) and the higher return on invested capital (0.00% vs −4,549.0%). Across the 11 metrics below, NeuroSense Therapeutics Ltd. leads on 8 and Longeveron Inc. on 3.

Valuation

Metric LGVN NRSN Biotechnology median
P/E n/m n/m 8.58
P/S 4.20 n/m 10.29
P/B 0.48 n/m 2.29
Price to free cash flow n/m n/m 21.93
EV/EBITDA 0.19 n/m 0.67
EV/Sales (3.63) n/m 9.89
Earnings yield (622.64%) (520.49%) (31.56%)
Free cash flow yield (417.71%) (568.39%) (23.42%)

Profitability

Metric LGVN NRSN Biotechnology median
Gross margin 69.76% — 65.77%
Operating margin (1,992.84%) 0.00% 0.00%
Net margin (1,977.59%) 0.00% 0.00%
Free cash flow margin (1,755.69%) 0.00% 0.00%
Return on equity (203.61%) 0.00% (54.09%)
Return on assets (145.64%) 0.00% (47.78%)
Return on invested capital (4,549.04%) 0.00% 0.00%

Growth

Metric LGVN NRSN Biotechnology median
Revenue growth (TTM) (42.74%) — 5.83%
EPS growth (last fiscal year) 50.76% 18.52% 29.36%
Revenue growth, 5-year CAGR (26.60%) — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric LGVN NRSN Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 2.63 0.28 4.80
Net debt to EBITDA 0.20 0.01 0.97

Dividend

Metric LGVN NRSN Biotechnology median
Dividend yield — — 0.44%
Payout ratio — — —

Size

Metric LGVN NRSN Biotechnology median
Market cap 5.07m 4.63m 153.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack